

September 9, 2024

Submitted electronically via: http://www.regulations.gov

The Honorable Chiquita Brooks-LaSure Administrator Centers for Medicare and Medicaid Services Attention: CMS–1807–P 7500 Security Boulevard P.O. Box 8016 Baltimore, MD 21244-8016

Re: CY 2025 Physician Fee Schedule Proposed Rule

Dear Administrator Brooks-LaSure:

The CardioVascular Coalition (CVC) appreciates the opportunity to offer its comments to the Centers for Medicare and Medicaid Services (CMS) on the proposed rule for the CY 2025 Physician Fee Schedule (CMS-1807-P). The mission of the CVC is to advance patient access to cardiovascular care, particularly as it relates to peripheral artery disease (PAD) and coronary artery disease (CAD). CVC Members include providers and industry representing physicians and staff in 45 states at over 378 centers where minimally-invasive cardiovascular care services occur.²

In the 2025 PFS Proposed Rule, CMS notes, "[I]nterested parties have presented us with high-level information suggesting that Medicare payment policies are directly responsible for consolidating privately owned physician practices and freestanding supplier facilities into larger health systems. As discussed in further detail below, CVC states at the outset that the 2025 PFS continues the trend of reimbursement cuts to interventional care in the office-based setting.

As such, CVC will providing comments relating to the following:

- Medicare Physician Fee Schedule Reimbursement for Office-Based Interventional Services is Increasingly Unsustainable
 - o PFS Reimbursement for 300 Office-Based Services is Less Than Direct Costs
- Limb Salvage Provider Deserts
- Removing Certain High-Cost Supplies and Equipment from the PFS is Key to PFS Reform

¹ Federal Register, 89 FR 61596 (July 31, 2024)

² For more information about CVC, please see https://www.cardiovascularcoalition.com/about-us

I. MEDICARE PHYSICIAN FEE SCHEDULE REIMBURSEMENT FOR OFFICE-BASED LIMB SALVAGE SERVICES IS INCREASINGLY UNSUSTAINABLE

The 2025 Medicare Physician Fee Schedule (PFS) Proposed Rule would impose yet another round of significant cuts to office-based interventionalists. Key drivers of these cuts within the 2025 PFS Proposed Rule include:

- Conversion Factor Cut. A carry-over 2.8% cut to the conversion factor from the 2021 PFS E/M policy (which has been phased by Congress since the policy was implemented). When finally phased-in, the 2025 conversion factor is projected to be \$32.3433, a cut of more than 10% from the \$36.09 conversion factor in 2020.
- Clinical Labor Cuts. The fourth year of clinical labor cuts to office-based intervention relative value units (RVUs) stemming from the phase-in through 2025 of the 2022 PFS clinical labor policy that cuts some interventional codes by another 5% in 2025.

PFS physician payments equal conversion factor *RVUs. As a result, key limb salvage services will again be cut by up to 8% in 2025 alone (see chart below). These year-over-year cuts are being implemented without regard to patient outcomes, actual PFS provider resource needs, or any other rationale policy.

CF		2024 Non-Facility Total RVU/Unit	cian Fee Schedule 33.29 2024 Non-Facility Total Payments	2025 Proposed P 2025 Non-Facility Total RVU/Unit	hysician Fee Schedule 32.36 2025 Non-Facility Total Payments	2025 Proposed RVU Difference	2025 Proposed Payment Difference
CPT	Procedure Description	(Final)	(Final)	(Proposed)	(Proposed)		
37220	Iliac revasc	74	\$2,452	71	\$2,296	-4%	-6%
37221	Iliac revasc w/stent	90	\$3,010		\$2,809	-4%	-7%
37222	Iliac revasc add-on	18	\$605	18	\$574	-2%	-5%
37223	Iliac revasc w/stent add-on	37	\$1,241	36	\$1,159	-4%	-7%
37224	Fem/popl revas w/tla	86	\$2,850	82	\$2,659	-4%	-7%
37225	Fem/popl revas w/ather	257	\$8,545	245	\$7,925	-5%	-7%
37226	Fem/popl revasc w/stent	238	\$7,915	227	\$7,337	-5%	-7%
37227	Fem/popl revasc stnt & ather	328	\$10,912	313	\$10,121	-5%	-7%
37228	Tib/per revasc w/tla	121	\$4,039		\$3,763	-4%	-7%
37229	Tib/per revasc w/ather	261	\$8,695	250	\$8,099	-4%	-7%
37230	Tib/per revasc w/stent	262	\$8,709	250	\$8,102	-4%	-7%
37231	Tib/per revasc stent & ather	345	\$11,498	328	\$10,625	-5%	-8%
37232	Tib/per revasc add-on	24	\$804	23	\$754	-4%	-6%
37233	Tibper revasc w/ather add-on	31	\$1,032	30	\$981	-2%	-5%
37234	Revsc opn/prq tib/pero stent	107	\$3,551	102	\$3,297	-4%	-7%
37235	Tib/per revasc stnt & ather	116	\$3,857	112	\$3,625	-3%	-6%
37236	Open/perq place stent 1st	81	\$2,686		\$2,513	-4%	-6%
37237	Open/perq place stent ea add	38	\$1,263	37	\$1,187	-3%	-6%
37238	Open/perq place stent same	101	\$3,372	97	\$3,146	-4%	-7%
37239	Open/perq place stent ea add		\$1,685		\$1,577	-4%	-6%
37252	Intrvasc us noncoronary 1st		\$927	27	\$863	-4%	-7%
37253	Intrvasc us noncoronary addl	5	\$170	5	\$165	-1%	-3%

Moreover, it is critical to understand that for many office-based interventionalists, these cuts in the 2025 PFS Proposed Rule come on top of significant cumulative cuts since 2006 (see Figure 1³.)




Figure 1

PFS Reimbursement for 300 Office-Based Services is Less Than Direct Costs

Cuts to office-based interventionalists have become so severe that, in 2024, there are 195 procedures across service lines that are paid at rates less than the direct costs associated with those procedures – as calculated by CMS itself. In the 2025 PFS Proposed Rule released in July, this number would grow to 300, a 50% increase. *In other words, for 300 services, CMS will not pay clinicians in private practice enough to cover the direct expenses of those services before even considering other costs like physician work and indirect costs (see Figure 2⁴⁵). It is important to underscore that all of these services are procedures performed outside of the hospital in the patient-preferred, community-based setting and that these services typically are the lowest cost option available to Medicare beneficiaries. Most of these services also utilize high-technology, high-cost supplies and equipment, the reimbursement for which under the PFS has been significantly eroded*

³ HMA analysis 2007-2025P Medicare Physician Fee Schedule Impact Tables. The values presented for 2021-2025P are adjusted to reflect the effects of the CAA, 2021, 2022, 2023, 2024.

⁴ Data is based on 2025 Physician Fee Schedule Proposed Rule Total Non-Facility Reimbursement and Total Direct Costs. Radiation Treatment Delivery data assumes 25 fractions for typical prostate cancer patient https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441303/.

⁵ For a full list of the 300 codes, please see Appendix I.

by the "direct cost adjustment" since 2007. In other words, since 2007, under the PFS, the immediate discount off total direct costs has increased from 33 percent to 56 percent. Since, according to the Medicare Payment Advisory Commission (MedPAC), direct costs only represent one-third of total practice costs, it is reasonable to assume that when indirect costs (i.e. overhead) are included, the number of office-based services under the PFS for which reimbursement is less than total practice costs is significantly higher than 300.6




Figure 2
Representative Examples Range Across Service Lines

This underfunding by the Medicare PFS of critical office-based services is a key catalyst for the growing site-of-service differentials between the hospital outpatient and office-based setting (see Figure 3⁷⁸). In 2019, the average payment for these same 300 codes reimbursed 43% more when performed in an outpatient hospital setting compared to an office setting. By 2024, this disparity had ballooned to 124% on average. As reimbursements for high-technology procedures decrease in the office setting, the same services provided in the hospital show significant increases. This dynamic further drives hospital consolidation and reduces the number of specialists in lower cost settings.


Figure 3

⁶ Medicare Payment Advisory Commission, Report to the Congress: Promoting Greater Efficiency in Medicare, June 2007, page 225

⁷ Reimbursement is calculated as the average PFS non facility fee compared to the average PFS facility fee plus the average HOPD OPPS fee

⁸ Graph shows 273 of the 300 codes where total reimbursement is less than direct costs. 27 CPT codes were excluded as they were added to the fee schedule after 2019.

Office Based Reimbursement and HOPD Reimbursement



REQUESTS: CVC requests CMS:

- Immediately address shortfalls in which PFS reimbursement is less than direct costs for at least 300 services in the PFS, including limb salvage;
- Truly "prioritize stability and predictability over ongoing updates" by freezing the final year of implementation of the clinical labor policy in 2025 that will result in further significant redistributions and instability to the Physician Fee Schedule;
- Implement MEI Rebasing to help offset ongoing cuts to office-based limb salvage; and
- Focus on fundamental PFS reform.

II. LIMB SALVAGE PROVIDER DESERTS

The U.S. Department of Health and Human Services, Health Resources and Services Administration defines primary care health professional shortage areas, in part, as "geographic areas [that] ... either have either have a population to full-time-equivalent primary care physician ratio of at least 3,500:1, or a population to full-time equivalent primary care physician ratio of less than 3,500:1 but greater than 3,000:1 and unusually high needs for primary care services or insufficient capacity of existing primary care providers."

As noted in a 2019 Health Affairs article, however, "to the extent that current policy interventions focus on expanding primary care but not specialist care in rural areas, they appear to be misguided and unlikely to reduce disparities in rural health outcomes. Notably, multiple studies have found

that regular treatment by specialist physicians in the ambulatory care setting is associated with better quality of care and reduced risk of death or hospitalization for people with chronic conditions. This does not detract from the value of primary care. However, access to primary care does not appear to drive rural-urban health outcome disparities."

CVC's 2024 review of information provided by Redi-data found significant specialty care deserts across a spectrum of interventional and diagnostic providers, including A) Urology, B) Cardiology, C) Radiation Oncology, D) Vascular Surgery, E) Interventional Radiology, and F) Diagnostic Radiology. ¹⁰ Importantly, according to this data, there are significant interventional and diagnostic provider deserts where there are NO such providers in the majority of counties in a majority of states. These deserts correspond to critical cuts to interventional providers described earlier in this comment letter. ¹¹

Ongoing cuts to interventional and diagnostic providers under the PFS are a key driver in the collapse of independent limb salvage providers and an ongoing catalyst of health system consolidation. CVC believes PFS reform must include policies to address these concerns, including policies to remove high-cost supply and equipment from the PFS.

III. REMOVING CERTAIN HIGH-COST SUPPLIES AND EQUIPMENT FROM THE PFS IS KEY TO FOR PFS REFORM

CVC's comments on options for PFS reform are in the context of several CMS requests for comments in the 2025 PFS Proposed Rule:

- [W]e request general information from the public on ways that CMS may continue work to improve the stability and predictability of any future updates. Specifically, we request feedback from interested parties regarding scheduled, recurring updates to PE inputs for supply and equipment costs.
- [W]e seek information about specific mechanisms that may be appropriate, and in particular, approaches that would leverage verifiable and independent, third party data that is not managed or controlled by active market participants.
- [W]e continue to encourage interested parties to provide feedback and suggestions to CMS that give an evidentiary basis to shape optimal PE data collection and methodological adjustments over time.

CVC's primary feedback to these requests is that – by its nature – the PFS is incapable of properly incorporating PE data into its reimbursement methodology. This is because the PFS was not set up to handle high-cost supplies and equipment. When the Medicare Physician Fee Schedule was adopted in 1992, policymakers did not anticipate technological advances would allow for advanced, high-tech, minimally invasive services in the office. Over the years, as

_

⁹ https://www.healthaffairs.org/doi/10.1377/hlthaff.2019.00838

¹⁰ https://www.redidata.com/

¹¹ For additional information on limb salvage deserts (including interventional radiology and vascular surgery), please see Appendix

scientific advances have allowed high-tech, high-cost supplies and equipment to move from the hospital to the community-based setting, the reimbursement for such supplies and equipment has not followed to the PFS. This dynamic has degraded the ability of the PFS to reimburse both for office-based interventional services as well as cognitive services, such as primary care. As a result of "budget neutrality," actions by policymakers in recent years to correct for reimbursement shortfalls in some areas of the PFS have eroded reimbursement for other PFS services.

As shown in Figure 4 below, while the IPPS, HOPPS and ASC Fee Schedules include only technical payments (e.g., the high-technology equipment, supplies and other innovations that have been a hallmark of the U.S. healthcare system) for HIPDs, HOPDs and ASCs, the PFS includes technical payments for office-based providers *plus* professional payments for physicians in all settings (e.g. HIPD, HOPD, ASC and office). As a result, PFS technical payments currently "budget-neutralize" office-based supply and equipment technicals to *dissimilar* professional payments for physician work in all sites-of-service (i.e. hospital, ASC and office). This dynamic is a significant contributor to the reimbursement cuts to office-based interventional services described earlier in this comment letter.

Figure 4

	Key Spending (Components of Major	Medicare Fee S	chedules
Site-of- Service	Hospital Inpatient Department	Hospital Outpatient Department	Ambulatory Surgical Center	Physician Office
Medicare Fee Schedule	Inpatient PPS	Hospital Outpatient PPS	ASC PPS	Physician Fee Schedule
Technical⊥	Included for the Hospital Inpatient setting	Included for the Hospital Outpatient setting	Included for the ASC setting	Included for the Office- Based setting
Professional+	Not Included	Not Included	Not Included	Included in the Physician Fee Schedule to reimburse for physician work in all sites of service (Inpatient PPS, Hospital Outpatient PPS, ASC PPS, and Physician Fee Schedule)

^{1 &}quot;Technical" refers to Medicare payments primarily for operating and capital costs, but excluding PFS payments for physician work.

Because most Medicare reimbursement for *hospital-based* services is derived from entirely distinct hospital inpatient and outpatient payment systems, ¹² hospital payment system reimbursement has grown faster than practice costs even as many PFS services literally are no longer reimbursed even for their costs. ¹³ This dynamic has been a key catalyst for consolidation: according to a 2021 AMA study, physician-owned practices have decreased 11% since 2012 as hospital ownership of these

^{+ &}quot;Professional" refers primarily to physician work as well as a small amount (i.e "facility" practice expense relative value units) intended to cover indirect expense of physician costs of operating a medical practice.

¹² The Hospital Inpatient Prospective Payment System and the Hospital Outpatient Prospective Payment System

¹³ American Medical Association, *Medicare physician payment is NOT keeping up with inflation*, April 2023 https://www.ama-assn.org/about/leadership/medicare-physician-payment-reform-long-overdue

Removing High-Tech Supply and Equipment from the PFS

For years, the AMA RUC has recommended "CMS separately identify and pay for high-cost disposable supplies priced more than \$500." CVC believes such an approach has merit. Removing high-tech supply and equipment services from the PFS could necessitate new "place of service" designations for such services and more appropriate inclusion in the larger ambulatory technical (i.e. OPPS/ASC) fee schedule. We believe the inclusion of certain high-tech supply and equipment services in the larger ambulatory technical (OPPS/ASC) fee schedule would the best way for CMS to provide an "evidentiary basis to shape optimal PE data collection and methodological adjustments over time," given previous CMS statements that, "we continue to seek the best broad based, auditable, routinely updated source of information regarding PE costs." Removing high-tech supply and equipment from the PFS also would free up resources within the PFS to achieve its primary raison d'être: reimbursement for physician work.

Reimbursing under the OPPS/ASC fee schedule for certain high-cost technical inputs used in office-based interventional care would stop further closures of independent limb salvage practices, given that the PFS effectively no longer covers such procedures. Importantly, such a policy also would (1) protect the PFS from further dilution from unsubsidized migration of high-cost supplies from the hospital and (2) provide additional resources for primary care as well as the overall PFS. Moreover, there is clear precedent for such action: in the 2010 PFS, the Centers for Medicare & Medicaid Services (CMS) finalized its proposal "to remove physician-administered drugs from the definition of physicians' services" due to the "significant and disproportionate impact that the inclusion of drugs has had on the SGR system." ¹⁷

REQUEST: We urge CMS to work with Congress on policies to establish a new site-of-service for office-based limb salvage to reimburse for the technical inputs utilized in such procedures under the OPPS/ASC fee schedule in order to help strengthen the PFS and protect independent physician practices.

CONCLUSION

We look forward to continuing to work with CMS to maintain and improve access to minimally-invasive cardiovascular care services while we strive to reduce racial and ethnic disparities in care and amputations overall. If you have additional questions regarding these matters and the views of the CVC, please contact Jason McKitrick at (202) 465-8711 or jmckitrick@libertypartnersgroup.com.

¹⁴ American Medical Association, *Recent Changes in Physician Practice Arrangements: Private Practice Dropped to Less Than 50 Percent of Physicians in 2020*, Carol K. Kane, PhD, June 2021

¹⁵ https://www.ama-assn.org/system/files/oct-2020-ruc-recommendations.pdf

¹⁶ 83 FR 59455

¹⁷ CY 2010 PFS Proposed and Final Rules. 74 FR 33650 and 74 FR 61965

CARDIOVASCULAR COALITION Joining Together for Patient Access























































APPENDIX I

Per et fia local d'en en 1915 (1916) de la contraction de la contr		300 CPI Codes where	ser	_	E Ye	mpursemen	 	otal Kelmbursement < Direct Costs in the PFS	n th	e Prs		
He there are all elicitors in the state of the control of the state of the control of the contro	036		37186	tomy add-on	50389	Remove renal tube w/fluoro	78140	Red cell sequestration	88185	Flowcytometry/tc add-on	93986	Dup-scan hemo compluni std
Peng der beset siden in griebe. 3719 in vernecht intrinspert in 6963. Enchange perpenditionly call helper der beset siden in guide. 3719 in vernecht intrinspert in 6963. Enchange perpenditionly call helper sident sident guide. 3719 in vernecht intrinspert in 6963. Enchange perpenditionly call helper sident sident guide. 3719 in vernecht intrinspert in 6963. Enchange perpenditionly call helper sident sident sident guide. 3719 in vernecht intrinspert sident side	980		37187		50431	Nix px nfrosgrm &/urtrgrm	78185	Spleen imaging	88313	Special stains group 2	93990	Doppler flow testing
Adjustmentation twenty intervent and an expression was acreal life. 1 Month of the control of th	286		37188		50434	Convert nephrostomy catheter		Platelet survival	88314	-ppe	94015	Patient recorded spirometry
Administration lower Nation 57129 Remark chross was to a registration of the control of part of parts of the control of parts of p	288		37191	cava filtr	50435	Exchange nephrostomy cath	78201	Liver imaging	88346	Imfluor 1st 1antb stain px	94644	Cbt 1st hour
Adjunctation lower jay brose 5719 Rennee intravious from controls. Should be compared to the control be control be compared to the control be compared to the control be control	983		37192		50592	Perc rfablate renal tumor	78202	Liver imaging with flow	88361	Tumor immunohistochem/compu		Evaluate pt use of inhaler
Authority browning part Authority ST 279 Intervation Distance halo Major ST 279 Intervation ST 270 Intervation ST 2	125		37193		50593	Perc cryo ablate renal tum	78215	Liver and spleen imaging	88364	Insitu hybridization (fish)	94669	Mechanical chest wall oscill
lear 1 or more levels of 7722 a liste renore, widere 7 \$232 or Cyptica ratio or other large and the proof learned	127		37197		50705	Ureteral embolization/occl	78226	Hepatobiliary system imaging	88367	Insitu hybridization auto	94761	Measure blood oxygen level
Anter of ig grave trig dev vo. 5722 in unite renow victoria 6.5826 increase of addition to the control of a c	215		37220		52284	Cysto rx balo cath urtl strx	78227	Hepatobil syst image w/drug	88369	M/phmtrc alysishquant/semiq	94762	Measure blood oxygen level
Antite de very 5722 illiace reveale dans on 5800 illiace reveale where a del con control and the control and t	527		37221		52442	Cystourethro w/addl implant	78231	Serial salivary imaging	88373	M/phmtrc alys ishquant/semiq	95012	Exhaled nitric oxide meas
Newgloand knochocopy 57224 Ferrypold rows within 4 doctors that the strate that intracement of the strate capability of t	278		37222		53855	Insert prost urethral stent	78232	Salivary gland function exam	88374	M/phmtrc alys ishquant/semiq	95024	lcut allergy test drug/bug
Beronth-buss sampleg Jarnose 5722 Fempopticenes with 6583 Ontoler provided by the control buss sampleg Jarnose 5722 Fempopticenes with 6583 Control buss sampleg Jarnose 5722 Fempopticenes with 6583 Control buss sampleg Jarnose 5722 Fempopticenes with 6583 Control buss sampleg Jarnose 5723 Fempopticenes with 6583 Control buss sampleg Jarnose 5723 Fempopticenes with 6583 Fempopticenes for presenting place of the control buss in register of the control buss sampleg Jarnose 5723 Fempopticenes with 6583 Fempopticenes of the control buss sampleg Jarnose 5723 Fempopticenes 6723 Fempo	627		37223		53860	Transurethralrftreatment	78261	Gastric mucosa imaging	88377	M/phmtrc alys ishquant/semiq	95065	Nose allergy test
Beronche busy and the control to the process where first a share for hydrocopy to the control to the process and the control to the process and the control to the process and	334		37224		55873	Cryoablate prostate	78264	Gastric emptying imag study	88381	Microdissection manual	95070	Bronchial allergy tests
Aboute plant whose period for 2722 ferry polit venes stirt, & ather 6 4883 in Contract to Make the time of the complete in the period for the complete in the	352		37225		55874	Tpml plmt biodegrdabl matrl	78265	Gastric emptying imag study	89230	Collect sweat for test	95145	Antigen therapy services
Abbite opan tumor per off of 2722 in Proposit events et nit d'aine (1865). Enformetial cryolabilen (1865). Relate palant tumor per off of 2722 in Proposit events what is a conservable (1865). Enformetial cryolabilen (1865). Relate palant tumor per off of 2722 in Proposition (1865). Hydracoccopy bisology (1865). Relate palant tumor per off of 2722 in Proposition (1865). Hydracoccopy bisology (1865). Relate palant tumor per off of 2722 in Proposition (1865). Hydracoccopy bisology (1865). Relate palant tumor per off of 2722 in Proposition (1865). Hydracoccopy bisology (1865). Relate palant tumor per off of 2722 in Proposition (1865). Hydracoccopy bisology (1865). Relate palant tumor per off of 2722 in Proposition (1865). Relate palant tumor per off of 2722 in Proposition (1865). Relate palant tumor per open (1865). R	108		37226		58340	Catheter for hysterography	78266	Gastric emptying imag study	91065	Breath hydrogen/methane test	95146	Antigen therapy services
Abbie pulm unno per off 5722 in Tubber recons owhither 6865 hydreacocopy biology. Response to the control of th	94		37227	stnt & ather	58353	Endometr ablate thermal	78278	Acute gi blood loss imaging	92977	Dissolve clot heart vessel	95147	Antigen therapy services
in leiler of the control of the cont	868		37228	tta	58356	Endometrial cryoablation	78290	Meckels divert exam	93005	Electrocardiogram tracing	95148	Antigen therapy services
Infection act vinography (\$723) Illuper revoke valents (\$660) Higher encode other many and the control of the c	85		37229		58558	Hysteroscopy biopsy	78300	Bone imaging limited area	93017	Cardiovascular stress test	95149	Antigen therapy services
Place catheter in vien 37223 (Popular de Jacob Sesso Hybracescopy statellization 7824) (Place catheter in vien) 57224 (Place catheter in vien) 57224 (Place received and of the Place catheter in vien) 57224 (Place cath	905		37230		58563	Hysteroscopy ablation	78306	Bone imaging whole body	93225	Ecg monit/reprt up to 48 hrs	95782	Polysom <6 vrs 4/> paramtrs
Place cutherer in view 37222 Revec opplying this per events and short as a state of the state of	110		37231	ather	58565	Hysteroscopy sterilization	78315	Bone imaging 3 phase	93226	Ecg monit/reprt up to 48 hrs	95783	Polysom <6 yrs cpap/bilvl
Place catheter in vain 5729 and the control of the catheter in vain 5729 and the control of the catheter in vain 5729 and the control of the catheter in artery 5729 and the catheter in artery 5724 and the catheter in arter	111		37232		58580	Transcrv abltj utrn fibrd rf	78451	Ht muscle image spect sing	93229	Remote 30 day ecg tech supp	95807	Sleep study attended
Place catheter in artery 77236 (Deprehenced start & show) Place catheter in artery 77236 (Operhenced start & show) Place catheter in artery 77236 (Operhenced start and 10030) Place catheter in artery 77236 (Operhenced start and 10030) Place catheter in artery 77236 (Operhenced start and 10030) Place catheter in artery 77236 (Operhenced start and 10030) Place catheter in nartery 77236 (Operhenced start and 10030) Place catheter in 10030) Place catheter	112		37234		5X007	Ablt trurl prst8 tis thrm us	78452	Ht muscle image spect mult	93241	Ext ecg>48hr<7d rec scan a/r	95808	Polysom any age 1-3> param
Place catheter in artery 77239 Open/per glace stern tash 67251 Carry on many place catheter in artery 77239 Open/per glace stern tash 67251 Carry on many catheter in artery 77239 Open/per glace stern tash 67251 Carry on many catheter in artery 77239 Open/per glace stern tash 67251 Carry on many catheter in artery 77239 Open/per glace stern tash 67251 Carry on many catheter in artery 77239 Open/per glace stern tash 67251 Carry on many catheter in artery 77239 Open/per glace stern tash 67251 Carry on many min 2007 Carry on many min 2007 Carry on many catheter in artery 77239 Open/per glace stern tash 67251 Carry on many catheter in artery 77239 Open/per glace stern tash 67251 Carry on many catheter in artery 77239 Open/per glace stern tash 67251 Carry on many catheter in artery 77234 Visc embolize/occulude blace of 27241 Carry on many catheter in artery 77241 Carry on many catheter in artery artery 77241 Carry on many catheter in artery 77241 Carry on many catheter in artery 67251	113		37235		5X008	Ablt trurl prst8 tis trnsdcr	78456	Acute venous thrombus image	93242	Ext ecg>48hr<7d recording	96446	Chemotx admn pertl cav impl
Place catheter in artery \$7228 Open/per of place stent a and \$7026 X. ray sman in 2 and 2 \$7026 Lung berifactor image (eff) \$7026 Care of Portion 1 \$7026 Care of Portion 2 \$7026 Care of Portion 2 \$7026 Care of Portion 2 \$7027 Care of Portion 2 \$7	114		37236		5XX05	Cysto insj dev ischmc rmdlg	78457	Venous thrombosis imaging	93243	Ext ecg>48hr<7d scan a/r	98975	Rem ther mntr 1st setup&edu
Establish access to access	115		37237	Г	70390	X-ray exam of salivary duct	78468	Heart infarct image (ef)	93245	Ext ecg>7d<15d rec scan a/r	98977	Rem ther mntr dv sply mscskl
Establish access to aorta \$722a Open/perioplace settine and add \$720 Open/perioplace and \$720 Open/perioplace and \$720 Open/perioplace and \$720 Open-perioplace open-perioplace and \$720 Open-perioplace open-perioplace and \$720 Open-perioplace open-periopl	140		37238		74251	X-ray xm sm int 2cntrst std	78579	Lung ventilation imaging	93246	Ext ecg>7d<15d recording	99153	Mod sed same phys/qhp ea
Place cath thoracis can act a 3724 Vusc embolize/occude venous \$7415 Ungraph Mrs display the state of the cath thoracis can act a 3724 Vusc embolize/occude venous \$7500 Contrast examt thoracic act at a 5724 Vusc embolize/occude organ \$7500 Contrast examt thoracic act at a 5724 Vusc embolize/occude organ \$7500 Contrast examt thoracic act at a 5724 Vusc embolize/occude organ \$7500 Contrast examt thoracic act at a 5724 Vusc embolize/occude organ \$7500 Contrast examt thoracic act at a 5724 Vusc embolize/occude organ \$7500 Contrast examt thoracic act at a 5724 Vusc embolize/occude organ \$7500 Contrast examt thoracic act at a 5724 Vusc embolize/occude organ \$7500 Contrast examt thoracic act at a 5724 Vusc example organ \$7500 Contrast examt thoracic act at a 5724 Vusc example organ \$7500 Contrast examt thoracic act at a 4724 Vusc example organ \$7500 Contrast examt thoracic act and thoracic act at a 4724 Vusc example organ \$7500 Contrast examt thoracic act at a 4724 Contrast examt thoracic act at a 4724 Contrast examt the antitat bill of contrast examt thoracic act act and trast examt the antitat venic act and a 5724 Contrast examt the antitat venic act and a 5724 Contrast examt the antitat venic act and a 5724 Contrast examt the act act and the act	091		37239		74400	Urography iv +-kub tomog	78598	Lung perf&ventilat diferentl	93247	Ext ecg>7d<15d scan a/r	99454	Rem mntr physiol param dev
Place cath thoracis a orta 37242 Vusse embolize/loccubde arteny 75600 Contrast examinatoric aorta 1 (2724) Vusse embolize/loccubde black 77078 Corbon contract cath thoracis and the cath and 1 (2724) Vusse embolize/loccubde black 77078 Corbon contract cath and 1 (2724) Vusse embolize/loccubde black 77078 Corbon contract cath and 1 (2724) Vusse embolize/loccubde black 77078 Corbon contract cath and 1 (2724) Vusse embolize/loccubde black 77078 Corbon contract cath and 1 (2724) Vusse embolize/loccubde black 77078 Corbon contract cath and 1 (2724) Vusse embolize/loccubde black 77078 Corbon contract cath and 1 (2724) Vusse embolize/loccubde black 77078 Corbon contract cath and 1 (2724) Vusse embolize/loccubde black 77079 Corbon contract cath and 1 (2724) Vusse embolize/loccubde black 77079 Corbon contract cath and 1 (2724) Vusse embolize/loccubde black 77079 Corbon contract cath and 1 (2724) Vusse embolize/loccubde black 77079 Corbon contract cath and 1 (2724) Vusse embolize/loccubde black 1 (2724) Vusse embolize/loccubde black (2725) Vusse embolize/loccubde black (2725) Vusse embolize/loccubde black (2725) Vusse embolize/loccubde black (2725) Vusse embolize/loccubde black (2726) Vusse embolize/loccubde vusse (2727) Vusse embolize/loccubde black (2727) Vusse embolize/loccubde vusse (2727) Vu	500		37241		74415	Urography nfs drip&/bls w/nf	78600	Brain image < 4 views	93268	Ecg record/review	99459	Pelvic examination
Inscath abdit ext ant 1st 1st 3724 Vusc embolize/loccude logan 79801 Remove vor device bostruct 78606 Brain image wiflow 4 + views 8 3224 (Expronitoring and naheysis in scath abdit ext ant 1st unitat 57244 Vusc embolize/loccudude logan 77290 Set radiation therapy field 76630 Cerebrospinal fluid scan 63224 (Rum internogle dym/dis 27244 Intrusous successions of the first of the fir	221		37242		75600	Contrast exam thoracic aorta	78601	Brain image w/flow < 4 views	93270	Remote 30 day ecg rev/report	G0166	Extrnl counterpulse, per tx
ins cath the art 1st bilat discussion below of 720. Set radiation therapy field for the art 1st bilat and 1st bilat	245		37243		75901	Remove cva device obstruct	78606	Brain image w/flow 4 + views	93271	Ecg/monitoring and analysis	G0238	Oth resp proc, indiv
ins cathren and 1st unitat 37.246 Trumb balo anglo) 1st art 77.290 Set radiation the range field Core derived point fluid scan 38.325 Deppler color flow add-on ins cathren and 1st billat 37.262 Include coloration 77.330 Radiation physics consult 78.656 Cart burn evaluation 93.464 Gordany atteny anglo sall ins cathren and 1nd billat 47.782 Percut abilitation physics consult 78.650 Cart burn evaluation 93.464 Coronary atteny anglo sall ins cathren and 2nd billat 47.782 Percut abilitation physics consult 78.650 Cart burn evaluation 93.464 Coronary atteny anglo sall Nix nonemptal socisors in value 47.782 Percut abilitation physics consult 78.650 Cart burn evaluation 93.70 Percut purn late changlo before cover analysis Nix nonemptal socisors in value 47.783 Percut purn late changlo before cover analysis 78.70 Radiology port image/sis 78.70 Richely imaging morphol 93.70 Frace age of the purn late changlo before cover analysis Indoor construction for challed before cover and ability of good and the changlo and act stent 77.71 Radiotogy port image/sis <	247		37244		77078	Ct bone density axial	78610	Brain flow imaging only	93296	Rem interrog evl pm/ids	G0239	Oth resp proc, group
In scath ran and 1st billar \$7252 Introse us noncoronary 1st 77332 Radiation physics consult 78645 Control and a c	251		37246		77290	Set radiation therapy field	78630	Cerebrospinal fluid scan	93325	Doppler color flow add-on	G0249	Provide inrtest mater/equip
Inscript ren art 2nd+ unitat 40800 Incision of tip fold 77372 Radiation physics consult 78645 Statum evaluation 89446 Coronary artery angle skill have consult 77382 Percut ablate liver 77372 Stis linear based 78660 Cot leakage imaging more consult 77383 Stis linear based 77363 Stis linear based 77364 Radiation of teach relation 77373 Stis linear based 77360 Kindwig more properties 77361 Radiation physics consult 77370 Radiation physics 77370	252		37252		77336	Radiation physics consult	78635	Csf ventriculography	93451	Right heart cath	G0288	Recon, cta for surg plan
Institute national building 47382 Percut abletic liver 77322 Strit fielder based 78660 Cafe leakage imaging 73646 Percut abletic liver 77322 Strit fielder 78600 Cafe leakage imaging morphol 73741 Redictogy port image 78600 Kidney imaging morphol 73741 Redictogy port image 78600 Redictogy 78600 Redictogy port image 78600 Redictogy 786	253		40806		77370	Radiation physics consult	78645	Csf shunt evaluation	93454	Coronary artery angio s&i	G0341	Percutaneous islet celltrans
Nik noncrapted scirant I vein 47538 Perq abtkjil vc ryobalbation 77347 Sant delivery 77800 Nuclean exam of tear flow 93701 Bloimpedance or analysis of processing and 17533 Perq abtkjil vc ryobalbation 77347 Radiology port images(s) 77800 Nuclean exam of tear flow 93701 Bloimpedance or analysis of processing from the chem at 17533 Removal builday of gcath 77610 Hyperthermia treatment 77800 Ribbourd of cetthere rise 17533 Removal builday of gcath 77610 Hyperthermia treatment 77800 Ribbourd of cetthere rise 17533 Removal builday of gcath 77701 Radiology port images(s) Ribbourd of cetthere rise 17533 Removal builday of gcath 77701 Radiology port images(s) Ribbourd of cetthere rise 17533 Removal builday of gcath 77701 Radiology port images(s) Ribbourd of cetther adhes 1st 47543 Removal builday of gcath 77701 Radiology port images(s) Ribbourd of the cetty images of the cetty of the cetty images of the cetty of the cetty images of the cetty of	254		47382		77372	Srs linear based	78650	Csf leakage imaging	93668	Peripheral vascular rehab	G2082	Visit esketamine 56m or less
Nik noncripord soft sert mit viv. 4753 injection for choloragiogram 77417 Radiology port inages (s) 7800 Kinkiney imaging incripol. 693786 Ambit by pmrttwiswiver conly forecast mine the choracy of the control of the	165		47383		77373	Sbrt delivery	78660	Nuclear exam of tear flow	93701	Bioimpedance cv analysis	G2083	Visit esketamine, > 56m
Endoworm there them adhes 1st voin 47536 Exchange billiany dig cath 77546 Hyperthermial treatment 78801 Robic city Lum2-area 1st dim 87536 Remorabilities of grade to the city Lum2-area 1st dim 47537 Remorabilities of grade to the city Lum2-area 1st dim 47537 Remorabilities of grade to the city Lum3-area 47548 Removabilities of grade to the city Lum3-area 47549 Removabilities of grade to the city Lum3-area 47540 Removabilities of grade to the city Lum3-area 47544 Removabilities of grade 47545 Removabilities of grade to the city Lum3-area	166		47531	E	77417	Radiology port images(s)	78700	Kidney imaging morphol	93786	Ambl bp mntr w/sw rec only	G6003	Radiation treatment delivery
Insertion of catheter vein 4753 Removal builary dig cath 77541 Hyperthermia treatment 78802 Relocation of catheter vein 4753 Removal builary dig cath 7759 Red did not stem 7759 Red did not stem 7759 Red did not stem 78013 Red did not stem 78023 Red del mass not stem 78023	173		47536		77610	Hyperthermia treatment	78801	Rp lockj tum 2+area 1+d img	93792	Pt/caregiver traing home inr	G6004	Radiation treatment delivery
Endowen the crhem adhes 1st 47538 Perq phint bile duct stent	181		47537		77615	Hyperthermia treatment	78802	Rp loc lzj tum whbdy 1 d img	93880	Extracranial bilat study	G6005	Radiation treatment delivery
Institute risk 5y	182	1st	47538		77790	Radiation handling	78803	Rp lockj tum spect 1 area	93922	Upr/Lxtremity art 2 levels	90099	Radiation treatment delivery
Comptribution picc risk 47544 Perq pinnt bile duct stent 79014 Thyroid met imaging wholeod flow 78008 Vinit a drug dx study 93924 Luw xr vass stoty bilat	572		47539		78013	Thyroid imaging w/blood flow	78804	Rp loc lzj tum whbdy 2+d img	93923	Upr/lxtr art stdy 3+ lvls	G6007	Radiation treatment delivery
Progravitation that account of the process of the p	84		47540		78014	Thyroid imaging w/blood flow	78808	Iv inj ra drug dx study	93924	Lwr xtr vasc stdy bilat	G6008	Radiation treatment delivery
Progavistator text sep acs 49186 Sclerox fluid collection 79018 Thyroid met imaging body 78821 Replacely turn spect 2 areas 93926 Lower extremity study Introducing cathed callection 79070 Parathyroid plans in maging 7XXX00 Mir stry imptificit and sep according to the collection of	36		47544		78016	Thyroid met imaging/studies	78830	Rp lockj tum spect w/ct 1	93925	Lower extremity study	G6009	Radiation treatment delivery
Intro-critical claysis circuit 49424 Resease cyst contrast inject 78007 Parathyroid planar imaging 7XX00 Mrst ympital/b asmit stril 93393 Upper extremity study ITM muchoris dialysis circuit 49424 Assess cyst contrast inject 78007 Adenal cortex & medula img 7XX00 Mrst ympital/b asmit stril 93931 Upper extremity study in this process cyst contrast inject 78103 Bone marrow imaging mut 7XX01 Mrst ympital/b asmit stril 93931 Upper extremity study in this process circuit 49460 Replace eg/ rube per 78110 Planar volume single 64466 Sint est utilisted aniquips eg 97397 Extremity study Red cell mass single 89120 Cyty ume 3.5 probes ea spec 93937 Extremity study Planar volume single 64460 Sint est utilisted aniquips ea 97397 Variety in the process of 97397 Planar volume single 97397 Planar volume single 97397 Planar volume single 97397 Planar volume single 97397 Variety volume 973979 Variety volume 97397 Variety volume 97397 Variety volume 973979 Variety volume 97397 Variety volume 97397 Variety volume 973979 Variety volume 97397 Variety volume 973979 Variety volume 97397 Variety volume 973979 Variety volume 97397 Variety volume 97397 Variety volume 97397 Variety volume 97397 Variety volume 973979 Variety volume 97397 Variety volume 97397 Variety volume 973979 Variety volume 97397 Variety volume 97397 Variety volume 973979 Variety volume 97397 Variety volume 97397 Variety volume 9739	337		49185		78018	Thyroid met imaging body	78831	Rp lockzj tum spect 2 areas	93926	Lower extremity study	G6010	Radiation treatment delivery
ThimbCrits dialysis circuit 49424 Assess cyst contrast inject 78075 Adrenal cortex & medulia ing 7XXX00 Mrstry implic&rib asmt str1 989391 Upper extremity study ThimbCrits dialysis circuit 49446 Change g-tube pric 781109 Plasma volume single 68466 Sikin est unlisted anigne 39371 Extremity study Plasma volume single 86466 Sikin est unlisted anigne 39371 Extremity study Plasma volume single 89120 Cyrp ure 3-5 probe sea spec 93978 Vascular study Revision tips Revision tips 89371 Red cell mass multiple 88121 Cyrp urine 3-5 probe sea spec 93978 Vascular study	903		49423		78070	Parathyroid planar imaging	78832	Rp lockzj tum spect w/ct 2	93930	Upper extremity study	G6011	Radiation treatment delivery
ThrmbChrist dialysis circuit 49446 Change grube to g perc 78108 Bone manrow imaging mult 7XXXX Misting might Misting might might Misting might Misting might Misting might misting misting might misting might misting might misting might misting misting might misting misti	904		49424		78075	Adrenal cortex & medulla img	7XX00	Mr sfty implt&/fb asmt stf 1	93931	Upper extremity study	G6012	Radiation treatment delivery
Stein print of dialysis seg 49450 Replace got tube per 7810 Plastan volume single 84486 Sont sets units of diagrams 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	906		49446	Ī	78103	Bone marrow imaging mult	7XX01	Mr stty mptt&/tb asmt strea	93970	Extremity study	G6013	Kadiation treatment delivery
Oldysis sincut emboy 4993 Replace duodyjej tube perc 78121 Red cell mass singe 88121 Cytp urine 3-5 probes capter 93979 Vascular study Revision tips 49452 Replace g.) tube perc 78121 Red cell mass multiple 88121 Cytp urine 3-5 probes captr 193979 Vascular study	806		49450		78110	Plasma volume single	86486	Skin test unlisted antign ea	93971	Extremity study	G6014	Radiation treatment delivery
MeVision rips 49492 Replace 8-1 tide perc 78321 Medicell mass multiple 66.121 Cytp unite 3-5 probes cripti 39979 Vascular study	200		TOTO	heic	70404	ned cell lidas siligle	00120	Cyth mile 3-3 phones ed spec	93970	Vascutal study	0000	hadiation to delivery limit
Constant Con	3/183		49452		78121	Red cell mass mutiple	88121	Cyth urine 3-5 probes cmptr	93979	vascutar study	90010	Delivery complimit

APPENDIX II





Medicare PFS Cuts to Vascular Surgery Since 2006 are -29% Counties with at least one Vascular Surgeon Counties with no Vascular Surgeon